InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a report released on Wednesday. The firm set a “sell” rating on the stock.

Separately, Lake Street Capital started coverage on shares of InspireMD in a research note on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective on the stock.

InspireMD Price Performance

Shares of NSPR stock opened at $2.74 on Wednesday. The business’s fifty day moving average is $2.86 and its 200 day moving average is $2.76. The stock has a market cap of $81.35 million, a price-to-earnings ratio of -3.65 and a beta of 0.88. InspireMD has a twelve month low of $1.81 and a twelve month high of $3.80.

Institutional Investors Weigh In On InspireMD

Hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC bought a new position in shares of InspireMD during the fourth quarter valued at $27,000. Legato Capital Management LLC purchased a new stake in InspireMD during the 4th quarter valued at about $47,000. Schonfeld Strategic Advisors LLC increased its stake in InspireMD by 153.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after purchasing an additional 18,233 shares in the last quarter. Northern Trust Corp raised its holdings in InspireMD by 103.7% in the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock worth $126,000 after buying an additional 24,452 shares during the last quarter. Finally, Essex Investment Management Co. LLC purchased a new position in InspireMD in the fourth quarter worth about $191,000. 44.78% of the stock is owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.